T riple-negative breast cancer (TNBC) accounts for about 10%-20% of all breast cancers, and it is negative for estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (1). Compared with other types of breast cancer, TNBC is considered more aggressive, with a higher recurrence rate and decreased overall survival (1,2). Within the TNBC group, pathologic complete response (pCR) to neoadjuvant systemic therapy (NAST) is strongly correlated with improved disease-free survival and overall survival (3). Because only about 20%-50% of participants with TNBC will achieve pCR, early assessment of the treatment response is beneficial (4-6). For example, participants with predicted non-pCR may be directed toward more aggressive or potentially more effective novel therapies at an early stage.The effectiveness of NAST is most commonly assessed by the change in tumor size based on conventional breast imaging (eg, mammography, US) and clinical examination (7). The appropriateness criteria of the American